SCHEMBL3203091

SCHEMBL3203091

CC1=CCC(c2ccccc2C=NNc2c(C)cc(C)cc2C)=C1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.34
RAB9A P51151 4/20 0.34
KMT2A Q03164 4/20 0.34
NPC1 O15118 3/20 0.34
MEN1 O00255 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 5/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 4/20 0.33
POLB P06746 1/20 0.32
HTT P42858 3/20 0.32
MAPK1 P28482 1/20 0.31
GFER P55789 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203084 1.00 MAPT (0.34) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3189286 0.86 MAPT (0.34) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3189281 0.86 MAPT (0.34) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3204602 0.86 MAPT (0.32) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3204605 0.86 MAPT (0.32) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3212249 0.84 MAPT (0.42) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3212242 0.84 MAPT (0.42) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3193112 0.82 MAPT (0.47) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3193103 0.82 MAPT (0.47) MAPTRAB9AKMT2ANPC1MEN1
SCHEMBL3193528 0.82 MAPT (0.32) MAPTRAB9AKMT2ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732643-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-08 US disclosed
US-7671226-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME HANAOKA HIDENORI 2010-02-25 US disclosed
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same HANAOKA HIDENORI 2009-02-26 US disclosed
US-7439379-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20040242410-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-12-02 US disclosed
EP-1426379-A1 TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same C1R, C1S, AP1M1 MAPT 2641/4885RAB9A 1759/4885KMT2A 2101/4885
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME C1R, C1S, AP1M1 MAPT 2641/4885RAB9A 1759/4885KMT2A 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.